177 related articles for article (PubMed ID: 6197357)
1. Control of immune complex and zymosan-mediated anaphylatoxin generation by proteins B and H of the alternative complement pathway.
Kings M; Nydegger UE; de Weck AL
Immunology; 1984 Jan; 51(1):123-31. PubMed ID: 6197357
[TBL] [Abstract][Full Text] [Related]
2. Control of the immune complex-complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin.
Spycher MO; Nydegger UE
Eur J Immunol; 1984 Mar; 14(3):276-9. PubMed ID: 6231187
[TBL] [Abstract][Full Text] [Related]
3. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
[TBL] [Abstract][Full Text] [Related]
4. The alternative complement pathway control protein H binds to immune complexes and serves their detection.
Nydegger UE; Corvetta A; Spaeth PJ; Spycher M
Clin Immunol Immunopathol; 1983 Jan; 26(1):56-65. PubMed ID: 6223741
[TBL] [Abstract][Full Text] [Related]
5. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
Kazatchkine MD; Fearon DT; Austen KF
J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
[No Abstract] [Full Text] [Related]
6. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
[TBL] [Abstract][Full Text] [Related]
7. Species specificity of recognition by the alternative pathway of complement.
Horstmann RD; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1985 Feb; 134(2):1101-4. PubMed ID: 3155536
[TBL] [Abstract][Full Text] [Related]
8. Complement activation requirements for histamine release from human leukocytes: influence of purified C3ahu and C5ahu on histamine release.
Hartman CT; Glovsky MM
Int Arch Allergy Appl Immunol; 1981; 66(3):274-81. PubMed ID: 6170591
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of C5 convertase by epsilon amino caproic acid (EACA): a limiting factor in the generation of C5a anaphylatoxin.
Vallota EH
Immunology; 1978 Mar; 34(3):439-47. PubMed ID: 417019
[TBL] [Abstract][Full Text] [Related]
10. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
DiScipio RG
Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
[TBL] [Abstract][Full Text] [Related]
11. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
12. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
Baker PJ; Parker CJ; Osofsky SG
Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
[TBL] [Abstract][Full Text] [Related]
13. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
14. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
Medof ME; Prince GM; Mold C
Proc Natl Acad Sci U S A; 1982 Aug; 79(16):5047-51. PubMed ID: 6214790
[TBL] [Abstract][Full Text] [Related]
15. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position.
Seifert PS; Kazatchkine MD
Mol Immunol; 1987 Dec; 24(12):1303-8. PubMed ID: 3431552
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces.
Carreno MP; Labarre D; Maillet F; Jozefowicz M; Kazatchkine MD
Eur J Immunol; 1989 Nov; 19(11):2145-50. PubMed ID: 2480904
[TBL] [Abstract][Full Text] [Related]
17. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
[TBL] [Abstract][Full Text] [Related]
18. Methylprednisolone inhibits the alternative and amplification pathways of complement.
Weiler JM; Packard BD
Infect Immun; 1982 Oct; 38(1):122-6. PubMed ID: 6754609
[TBL] [Abstract][Full Text] [Related]
19. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
Schenkein HA; Ruddy S
J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
[No Abstract] [Full Text] [Related]
20. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
